Tumor Necrosis Factor-Alpha

PHILADELPHIA — Compared with controls, patients with chronic kidney disease showed greater accumulation of intermuscular adipose tissue that has a strong association with insulin resistance, according to data presented at ASN Kidney Week.

While tumor necrosis factor-alpha inhibitors have shown positive results in the treatment of acne, the use of these inhibitors for other conditions may incite new acne development, according to a study.

Patients with immune mediated diseases and treated with tumor necrosis factor-alpha inhibitors have a modest risk for new onset psoriasis, according to a study.

SAN ANTONIO — Entyvio was associated with significantly fewer serious adverse events and serious infections compared with anti-TNF therapy in biologic-naive patients with inflammatory bowel disease, according to data from the EVOLVE trial presented at the American College of Gastroenterology Annual Meeting.

SAN ANTONIO — Older patients with Crohn’s disease were less likely to receive biologic agents and more than twice as likely to receive mesalamine compared with younger patients, according to data presented at the American College of Gastroenterology Annual Meeting.

The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.